A director at Recordati bought 21,050 shares at 47.495EUR and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
In today's Morning Views publication we comment on developments of the following high yield issuers: Vallourec, Rekeep, Advanz Pharma, Kelvion (formerly Galapagos Holding), Recordati, Lecta, Clarios, Ardagh, Crown Holdings, TUI, David Lloyd Leisure, Centrient, Azelis
Carrefour has reportedly received three offers for its Romanian business, including one from Auchan.|Permira is reportedly negotiating the sale of Golden Goose for more than € 2.5bn to Hongshan|Edenred has significantly revised downwards its EBITDA forecast for 2026 if regulatory changes in Brazil are confirmed.|
Carrefour aurait reçu trois offres pour son activité en Roumanie dont une d’Auchan.|Permira négocierait la cession de Golden Goose au fond Hongshang Capital pour plus de 2,5 mds EUR|Edenred revoit en forte baisse sa prévision d’EBITDA pour 2026 si les changements règlementaires au Brésil venaient à être confirmés.|
In today's Morning Views publication we comment on developments of the following high yield issuers: Sunrise, Bite, TK Elevator, Italmatch Chemicals, Nimlas, Lowell, Intralot, Recordati, Klockner Pentaplast, Standard Profil, Advanz Pharma, Softbank Group, Ineos
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION NEWS RELEASE RECORDATI FIRST NINE MONTHS 2025 RESULTS:REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION Consolidated net revenue of € 1,956.2 million in the first nine months of 2025, +12.2% or +8.1% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 743.9 million, +11.8%, margin on revenue of 38.0%Adjusted ne...
RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER NEWS RELEASE Milan, 23 October 2025 – Recordati, a global pharmaceutical company, announces today that Mike McClellan will join as its new Chief Financial Officer (CFO) as of January 1, 2026 and will be based in the Group’s headquarters in Milan. Mike McClellan, an American national, is a seasoned CFO in the pharmaceutical industry with nearly 30 years of experience across various geographies. Most recently, he served as CFO of Almirall (2019-2025) where he played a pivotal role in delivering sustained growth and profitabi...
Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in Paediatric Oncology The 2026 Award is focused on research in paediatric oncology, specifically sarcomasPaediatric sarcomas are among the leading causes of cancer-related death in children, yet there has been little innovation in treatment progress over the past 40 yearsThe winning project will be awarded a research grant of €250,000Applications are open to young investigators of all nationalities until 31 January 2026 – all information available at prize.recordati.com Milan, 21st October 2025 – Recordati S.p.A...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.